Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$468M |
| 2 |
Johnson & Johnson
JNJ
|
+$440M |
| 3 |
IBM
IBM
|
+$355M |
| 4 |
Booking.com
BKNG
|
+$332M |
| 5 |
RAI
Reynolds American Inc
RAI
|
+$331M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LLTC
Linear Technology Corp
LLTC
|
+$482M |
| 2 |
Walt Disney
DIS
|
+$247M |
| 3 |
Visa
V
|
+$219M |
| 4 |
Deere & Co
DE
|
+$200M |
| 5 |
Johnson Controls International
JCI
|
+$179M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.02% |
| 2 | Technology | 13.31% |
| 3 | Financials | 12.25% |
| 4 | Industrials | 9.65% |
| 5 | Consumer Staples | 9.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
2376
DELISTED
Blueprint Medicines
BPMC
| $1.5M | ﹤0.01% |
37,400
+26,900
| +256% | +$963K |
|
|
MRIN
2377
DELISTED
Marin Software
MRIN
| $1.49M | ﹤0.01% |
19,755
-150
| -0.8% | -$13.2K |
|
2378
Wayfair
W
$13.9B
| $1.49M | ﹤0.01% |
36,800
+11,700
| +47% | +$462K |
|
|
IMBI
2379
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
| $1.49M | ﹤0.01% |
116,406
+7,610
| +7% | +$102K |
|
2380
TAT Technologies
TATT
$517M
| $1.49M | ﹤0.01% |
151,800
+5,500
| +4% | +$47.9K |
|
|
TIS
2381
DELISTED
Orchids Paper Products, Inc.
TIS
| $1.49M | ﹤0.01% |
62,000
-187,245
| -75% | -$5.05M |
|
|
ARCX
2382
DELISTED
Arc Logistics Partners LP
ARCX
| $1.49M | ﹤0.01% |
104,441
+77,656
| +290% | +$1.2M |
|
|
PCO
2383
DELISTED
Pendrell Corporation - Class A
PCO
| $1.49M | ﹤0.01% |
2,287
+666
| +41% | +$436K |
|
2384
Twin Disc
TWIN
$349M
| $1.48M | ﹤0.01% |
72,000
-18,300
| -20% | -$333K |
|
2385
Kforce
KFRC
$1.04B
| $1.48M | ﹤0.01% |
62,300
-51,000
| -45% | -$1.22M |
|
|
I
2386
DELISTED
INTELSAT S. A.
I
| $1.48M | ﹤0.01% |
355,800
+164,200
| +86% | +$619K |
|
2387
Axogen
AXGN
$2.57B
| $1.47M | ﹤0.01% |
+140,951
| New | +$1.44M |
|
2388
Saia
SAIA
$10.1B
| $1.47M | ﹤0.01% |
33,198
+26,898
| +427% | +$1.26M |
|
2389
Tredegar Corp
TG
$276M
| $1.47M | ﹤0.01% |
83,800
-23,900
| -22% | -$498K |
|
|
EIGI
2390
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $1.47M | ﹤0.01% |
187,400
+174,800
| +1,387% | +$1.43M |
|
|
JNP
2391
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $1.47M | ﹤0.01% |
309,500
+55,200
| +22% | +$279K |
|
|
ONIT
2392
Onity Group
ONIT
$327M
| $1.47M | ﹤0.01% |
17,905
-37,448
| -68% | -$2.86M |
|
2393
Preformed Line Products
PLPC
$2.27B
| $1.47M | ﹤0.01% |
28,100
+1,700
| +6% | +$87.1K |
|
2394
VanEck Gold Miners ETF
GDX
$26.8B
| $1.46M | ﹤0.01% |
64,200
-374,600
| -85% | -$8.71M |
|
2395
Harvard Bioscience
HBIO
$30M
| $1.46M | ﹤0.01% |
56,050
+3,130
| +6% | +$90.2K |
|
2396
Flex
FLEX
$46.7B
| $1.45M | ﹤0.01% |
114,520
-22,763
| -17% | -$273K |
|
2397
Rocky Brands
RCKY
$354M
| $1.45M | ﹤0.01% |
125,200
-10,700
| -8% | -$123K |
|
2398
Landmark Bancorp
LARK
$197M
| $1.45M | ﹤0.01% |
73,659
+6,826
| +10% | +$131K |
|
2399
Phibro Animal Health
PAHC
$1.38B
| $1.44M | ﹤0.01% |
51,400
+37,500
| +270% | +$1.06M |
|
2400
Gorman-Rupp
GRC
$2.13B
| $1.44M | ﹤0.01% |
45,800
+5,400
| +13% | +$168K |
|
Similar funds
Jim Simons's Q1 2017 Portfolio in Review
As of Q1 2017, Jim Simons held 3,652 positions worth $71.6B, up 13% from $63.2B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Jim Simons deployed $5.19B of net new capital in Q1 2017, opening 433 new positions and adding to 1,585 existing holdings. Its largest new stake was Merck: 7,716,460 shares worth $468M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Walt Disney, an estimated $247M trimmed.
- Jim Simons's largest Q1 2017 buy was Merck: 7,716,460 shares worth $468M.
- Jim Simons added most to Johnson & Johnson in Q1 2017, an estimated $440M increase.
- Jim Simons's biggest Q1 2017 reduction was Walt Disney, cutting an estimated $247M.
- Jim Simons fully exited Linear Technology Corp in Q1 2017, selling an estimated $482M.
- Jim Simons's ten largest holdings make up 7.9% of its $71.6B portfolio in Q1 2017.
- Jim Simons opened 433 new positions and closed 462 in Q1 2017.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $71.6B.
Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.